HT1080-eGFP-Puro is a polyclonal population of the human fibrosarcoma cell line HT1080 (ATCC® CCL-121™). To achieve stable reporter expression in the polyclonal population, parental HT1080 cells were transduced with LV-eGFP-PGK-Puro (LV031) and selected using puromycin. LV-eGFP-PGK-Puro encodes the enhanced green fluorescent protein (eGFP) cDNA under the spleen focus-forming virus (SFFV) promoter and the puromycin resistance gene (Puro) under the mouse phosphoglycerate kinase (PGK) promoter.

*The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.

This cell line has been tested for mycoplasma contamination and is certified mycoplasma free.

The parental HT1080 cell line has been authenticated and certified free of interspecies cross contamination by short tandem repeat (STR) profiling with 9 STR loci.

Replication Competent Lentivirus (RCL) Test (including a test report) is available for this cell line at an added cost.  Contact us to learn more.

Morphology

Low and high density cell morphology (200x)

eGFP Expression

HT1080-eGFP-Puro (green) or control (HT1080-Fluc-Puro) cells were fixed with paraformaldehyde and analyzed by flow cytometry (20,000 events).

Complete Growth Medium: DMEM supplemented with 10% FBS, 1X Penicillin/Streptomycin, and 1 µg/mL puromycin.

The addition of puromycin to the complete growth medium maintains high reporter expression over continued passage of the cells. It is highly recommended, especially if the cells undergo multiple passages prior to being used for studies.

These cells should be grown in the indicated medium and passaged when they reach confluency. For routine passaging, cells are recommended to be split at a 1:10 ratio every 3-4 days.

These cells are suitable for in vitro and in vivo experimentation.

HT1080 cells are a xenograph model for fibrosarcoma and form primary tumors and distant metastases (lung, liver, and brain) post implantation into immunosuppressed mice.^1,2

eGFP is not recommended for whole animal in-live imaging. Rather, samples can be collected postmortem for analysis by conventional fluorescence microscopy or flow cytometry.

The cells can be amplified in vitro and used to generate additional frozen stocks. Cryopreservation of low passage stocks is recommended. Frozen stocks should be preserved in a designated cryopreservation medium.

These cells were generated via lentiviral vector transduction. The lentiviral vector used for transduction was a self-inactivating (SIN) vector in which the viral enhancer and promoter have been deleted. Transcription inactivation of the LTR in the SIN provirus increases biosafety by preventing mobilization by replication competent viruses and enables regulated expression of the genes from the internal promoters without cis-acting effects of the LTR³. Nevertheless, all work with these cells should be performed under biosafety-level 2 (BSL2) conditions by trained personnel. Institutional requirements may permit handling of these cells under BSL1 conditions if certain criteria are met.

References:
¹Rasheed et al. Cancer. 1974. 33:1027-1033.
²Praus et al. Gene Therapy. 1999. 6:227-236.
³Miyoshi et al. J Virol 1998. 72:8150-8157.